NLSP | NLS Pharmaceutics AG Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.19 - 3.49
52 Week Range	3.00 - 29.08
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	26,874
Average Volume	211,149
Shares Outstanding	2,472,440
Market Cap	8,237,923
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-01-29

Valuation
Profitability
Growth
Health
P/E Ratio	-0.49
Forward P/E Ratio	N/A
EPS	-6.74
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	Switzerland
Website	NLSP

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

NLSP's peers: CRDF, ENTX, KZIA, NRBO, INDP, KTTA, QNRX, LIXT, ANEB, NGENF, ACRV, PTIX, MIRO, RZLT, HCWB, ELYM, MOLN, ASMB, NLTX, TIL, CTMX, ACHL, SLS, NLSPW

*Chart delayed

Analyzing fundamentals for NLSP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NLSP Fundamentals page.

Watching at NLSP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NLSP Technicals page.